BRPI0411290A - formulações para tratamentos da dor baseados em opióides contendo derivados substituìdos da 1,4-di-piperidin-4-il-piperazina - Google Patents

formulações para tratamentos da dor baseados em opióides contendo derivados substituìdos da 1,4-di-piperidin-4-il-piperazina

Info

Publication number
BRPI0411290A
BRPI0411290A BRPI0411290-3A BRPI0411290A BRPI0411290A BR PI0411290 A BRPI0411290 A BR PI0411290A BR PI0411290 A BRPI0411290 A BR PI0411290A BR PI0411290 A BRPI0411290 A BR PI0411290A
Authority
BR
Brazil
Prior art keywords
pain
opioid
treatment
piperidin
piperazine derivatives
Prior art date
Application number
BRPI0411290-3A
Other languages
English (en)
Inventor
Frans Eduard Janssens
Francois Maria Sommen
Beno T Christian Albert Boeck
Joseph Elisabeth Leenaerts
Yves Emiel Maria Va Roosbroeck
Theo Frans Meert
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33547567&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0411290(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of BRPI0411290A publication Critical patent/BRPI0411290A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4468—Non condensed piperidines, e.g. piperocaine having a nitrogen directly attached in position 4, e.g. clebopride, fentanyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

"FORMULAçõES PARA TRATAMENTOS DA DOR BASEADOS EM OPIóIDES CONTENDO DERIVADOS SUBSTITUìDOS DA 1,4-DI-PIPERIDIN-4-IL-PIPERAZINA". A presente invenção refere-se a novas formulações para tratamentos da dor e/ou nocicepção baseados em opióides contendo analgésicos opióides e derivados da 1,4-di-piperidin-4-il-piperazina tendo atividade antagonística com a neuroquinina, em particular atividade antagonística com NK~ 1~, uso da referida formulação para a fabricação de um medicamento para a prevenção e/ou tratamento da emese, dor e/ou nocicepção, em particular nos tratamentos da dor aguda ou crónica baseada em opióides, mais em particular nos tratamentos da dor inflamatória, pós-operatória, na sala de emergência (SE), ruptura, neuropática e do câncer e o uso de um anatagonista do receptor NK~ 1~, para a fabricação de um medicamento para a prevenção e/ou tratamento da depressão respiratória nos tratamentos da dor baseados em opióides. As formulações farmacêuticas de acordo com a invenção incluem um veículo farmaceuticamente aceitável e, como ingredientes ativos uma quantidade terapeuticamente efetiva de um analgésico opióide e antagonistas do NK~ 1~ de acordo com a fórmula geral (I) seus sais de adição com ácido ou base farmaceuticamente aceitáveis, as suas formas estereoquimicamente isoméricas, a sua forma de N-óxido e suas pró-drogas, na qual todos os substituintes são definidos conforme na reivindicação 1. A composição farmacêutica de acordo com a invenção reduz em grande parte uma série de efeitos colaterais indesejáveis associados com os analgésicos opióides, em particular a emese, a depressão respiratória e a tolerância, aumentando assim a tolerabilidade total dos referidos opióides no tratamento da dor.
BRPI0411290-3A 2003-06-10 2004-06-07 formulações para tratamentos da dor baseados em opióides contendo derivados substituìdos da 1,4-di-piperidin-4-il-piperazina BRPI0411290A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP0350220 2003-06-10
PCT/EP2004/051048 WO2004110415A2 (en) 2003-06-10 2004-06-07 Substituted 1, 4-di-piperidin-4-yl-piperazine derivative combined with an opioid analgesic and their use for the treatment of pain and side-effects associated with opioid-based treatments

Publications (1)

Publication Number Publication Date
BRPI0411290A true BRPI0411290A (pt) 2006-08-29

Family

ID=33547567

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0411290-3A BRPI0411290A (pt) 2003-06-10 2004-06-07 formulações para tratamentos da dor baseados em opióides contendo derivados substituìdos da 1,4-di-piperidin-4-il-piperazina

Country Status (16)

Country Link
US (1) US20060128721A1 (pt)
EP (1) EP1635811A2 (pt)
JP (1) JP2006527236A (pt)
KR (1) KR20060006098A (pt)
CN (1) CN1822828A (pt)
AR (1) AR044490A1 (pt)
AU (1) AU2004246817A1 (pt)
BR (1) BRPI0411290A (pt)
CA (1) CA2527856A1 (pt)
CL (1) CL2004001421A1 (pt)
IL (1) IL172423A0 (pt)
MX (1) MXPA05013295A (pt)
MY (1) MY144580A (pt)
TW (1) TW200510382A (pt)
WO (1) WO2004110415A2 (pt)
ZA (1) ZA200510044B (pt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2485B1 (en) * 2002-12-23 2009-01-20 شركة جانسين فارماسوتيكا ان. في 1-Piperidine-3-Yl-4-Piperidine-4-Yl-Piperazine derivatives substituted and used as quinine antagonists
FR2879460B1 (fr) * 2004-12-17 2007-02-23 Sod Conseils Rech Applic Associations anti-douleur comprenant un derive de dihydroimidazopyrazine
US7880002B2 (en) 2004-12-29 2011-02-01 Millennium Pharmaceuticals, Inc. Substituted piperazinyl-pyrrolidine compounds useful as chemokine receptor antagonists
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
NZ556629A (en) * 2005-03-03 2010-04-30 Janssen Pharmaceutica Nv Substituted oxa-diaza-spiro-[5.5]-undecanone derivatives and their use as neurokinin antagonists
DE602006016244D1 (de) 2005-03-08 2010-09-30 Janssen Pharmaceutica Nv Diazaspiro-ä4,4ü-nonanderivate als neurokinin-(nk1)-antagonisten
EP2021005A4 (en) * 2006-05-03 2009-11-25 Cnsbio Pty Ltd METHOD AND COMPOSITION FOR THE TREATMENT OF INFLAMMATORY PAIN
US7842662B2 (en) 2006-11-10 2010-11-30 Cara Therapeutics, Inc. Synthetic peptide amide dimers
TWI522101B (zh) * 2012-04-17 2016-02-21 普渡製藥有限合夥事業 處理由類鴉片引起之不利的藥效動力反應之系統和方法
ES2675215T3 (es) 2013-02-08 2018-07-09 General Mills, Inc. Productos alimentarios reducidos en sodio
CN105209436B (zh) * 2013-03-15 2019-02-01 南洋理工大学 3-哌啶酮化合物及其作为神经激肽-1(nk1)受体拮抗剂的用途
RU2617409C1 (ru) * 2015-12-24 2017-04-25 Федеральное государственное бюджетное учреждение науки Институт элементоорганических соединений им. А.Н. Несмеянова Российской академии наук (ИНЭОС РАН) Амиды акриловой и метакриловой кислот с n-алкилпиперазино-пиперидинами и способ их получения
CN108503579B (zh) * 2018-03-28 2021-03-26 南京医科大学 芬太尼类似物及其应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2287404A (en) * 1994-03-15 1995-09-20 Pfizer Antiinflammatory and analgesic compositions
GB9426102D0 (en) * 1994-12-23 1995-02-22 Merck Sharp & Dohme Pharmacuetical compositions
NZ321575A (en) * 1995-10-30 1999-05-28 Janssen Pharmaceutica Nv 1-(1,2-disubstituted piperidinyl)-4- substituted piperazine derivatives
WO1997025988A1 (en) 1996-01-17 1997-07-24 Eli Lilly And Company Methods of treating or preventing pain or nociception
WO2001030348A1 (en) 1999-10-25 2001-05-03 Janssen Pharmaceutica N.V. Use of substance p antagonists for influencing the circadian timing system
US6642226B2 (en) 2001-02-06 2003-11-04 Hoffman-La Roche Inc. Substituted phenyl-piperidine methanone compounds
MY141736A (en) * 2002-10-08 2010-06-15 Elanco Animal Health Ireland Substituted 1,4-di-piperidin-4-yi-piperazine derivatives and their use as neurokinin antagonists

Also Published As

Publication number Publication date
AU2004246817A1 (en) 2004-12-23
ZA200510044B (en) 2007-04-25
MXPA05013295A (es) 2006-03-09
WO2004110415A2 (en) 2004-12-23
TW200510382A (en) 2005-03-16
KR20060006098A (ko) 2006-01-18
US20060128721A1 (en) 2006-06-15
AR044490A1 (es) 2005-09-14
IL172423A0 (en) 2006-04-10
WO2004110415A3 (en) 2005-02-10
MY144580A (en) 2011-10-14
CA2527856A1 (en) 2004-12-23
JP2006527236A (ja) 2006-11-30
CL2004001421A1 (es) 2005-05-27
EP1635811A2 (en) 2006-03-22
CN1822828A (zh) 2006-08-23

Similar Documents

Publication Publication Date Title
Saunders et al. Systematic review of antimicrobials, mucosal coating agents, anesthetics, and analgesics for the management of oral mucositis in cancer patients
Minkowitz et al. Pharmacokinetics of sublingual sufentanil tablets and efficacy and safety in the management of postoperative pain
CA3005150C (en) Topical film-forming spray
HRP20210487T1 (hr) Farmaceutski sastavi koji sadrže lokalni anestetik kao što je bupivakain za lokalnu primjenu u usta ili grlo
EP1102589B1 (en) Topical compositions comprising an opioid analgesic and an nmda antagonist
ES3064839T3 (en) Combination of cannabidiol and buprenorphine and its use for the treatment of chronic pain
CA2661759A1 (en) Buprenophine-wafer for drug substitution therapy
BRPI0513300A (pt) forma farmacêutica oral, protegida frente ao abuso, contendo (1r, 2r)-3-(3-dimetilamino-1-etil-2-propil)-fenol
CY1110495T1 (el) Χρηση ενος αγωνιστη υποδοχεα nmda για τη θεραπεια εμβοης που προκαλειται απο κοχλιακη διεγερτοτοξικοτητα
Tuite et al. Recent developments in the pharmacological treatment of Parkinson’s disease
BRPI0518622A2 (pt) usos de antagonistas de receptor do tipo 1 de interleucina-1(il-1r1) para a fabricaÇço de um medicamento para o tratamento de uma doenÇa respiratària; composiÇço farmacÊutica que compreende um antagonista do il-1r1 e um veÍculo fisiologicamente aceitÁvel e dispositivo de liberaÇço de medicamento
JP2009525343A5 (pt)
BR0009437A (pt) Amido pré-gelatinizado em uma formulação de liberação controlada
JP4832045B2 (ja) メキタジン、イブプロフェン及びトラネキサム酸含有医薬組成物
KR20140059240A (ko) 부프레노르핀 운반용 약물남용 억제 점막 부착 장치
BRPI0411165A (pt) composição farmacêutica, forma de unidade de dosagem e métodos para preparar seu uso
EP3160464B1 (en) 6-hydroxybuspirone for use in the treatment of movement disorders
BR0315098A (pt) Derivados de 1,4-dipiperidin-4-il-piperazina, uso dos mesmos, composição farmacêutica e processos para a preparação da mesma e dos referidos derivados
BR112023000798A2 (pt) Composições farmacêuticas compreendendo venglustat
AU2017263253A1 (en) Drug delivery system for the delivery of antiviral agents
TW200510382A (en) Novel formulations for opioid-based treatments of pain comprising substituted 1, 4-di-piperidin-4-yl-piperazine derivatives
JP2021138703A (ja) オピオイドとｎ−アシルエタノールアミンの組み合わせ
CN105407925A (zh) 用于泡腾剂型的制造工艺
AR044491A1 (es) Formulaciones para tratamientos de base opioidea para el dolor, que comprenden derivados de piperazina 1-( piperidinil 1,2- disustituido) - 4 - sustituidos
BRPI0908988A2 (pt) formulação galênica oral incluindo cetorolaco e vitaminas do complexo b, em que a vitamina b6 está em uma camada externa separada do resto dos princípios ativos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2129 DE 25/10/2011.